Treatment of the blastic crisis of chronic myelogenous leukemia with the combination of vindesine and prednisolone, and cytosine arabinoside.
Sixteen patients with chronic myelogenous leukemia in blast crisis were classified into three subgroups on the basis of blast cell morphology and a relation to the chemotherapeutic responsiveness was investigated. All of the four patients with lymphoid morphology, and seven of the eight with myeloid morphology (88%) achieved complete remission while none of the four with monocytoid morphology achieved complete remission.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003561:Cytarabine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000473:pathology; D011239:Prednisolone / Q000627:therapeutic use*; D014747:Vinblastine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014751:Vindesine
D000970:Antineoplastic Agents; D003561:Cytarabine; D014747:Vinblastine; D011239:Prednisolone; D014751:Vindesine